Feinstein Institutes' Mitochondria Transplantation Boosts Heart Recovery Post-Cardiac Arrest — The Feinstein Institutes for Medical Research

Event summary

Feinstein Institutes' study shows intravenous mitochondria transplantation (MTx) significantly improves heart function and organ protection in large-animal models of cardiac arrest.
Single IV dose of mitochondria enhanced the heart's pumping ability, raised blood pressure without vasopressors, and reduced multi-organ damage.
Research led by Kei Hayashida, MD, PhD, and Lance B. Becker, MD, published as a letter to the editor in AJRCCM on August 10, 2026.
Study builds on previous rodent model success, marking progress toward clinical translation for post-cardiac arrest syndrome.

The big picture

This study represents a significant advancement in addressing the critical gap in post-cardiac arrest care, where current treatments primarily focus on circulation without targeting cellular damage. The success in large-animal models suggests potential to transform outcomes for the approximately 10% of out-of-hospital cardiac arrest survivors who often face severe neurological or organ damage.

What we're watching

Clinical Translation: The pace at which this large-animal model success will transition to human clinical trials and regulatory approval.
Market Potential: Whether mitochondria transplantation can become a standard therapy for cardiac arrest given the current survival rates and organ damage challenges.
Competitive Landscape: How this innovation positions Feinstein Institutes against other research institutions developing mitochondrial therapies or alternative treatments for cardiac arrest.